Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
177people in the Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes. trial, from 2005
39of them with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
1.25 mg/day liraglutide
placebo
Reported higher first-phase insulin secretion, no range given+118
Reported higher arginine-stimulated insulin secretion, no range given+114
randomisedThe trial randomly assignedassigned by chance
1.9 mg/day liraglutide
placebo
Reported higher first-phase insulin secretion, no range given+103
Reported higher arginine-stimulated insulin secretion, no range given+94.0
randomisedthe abstract, start to end
… first-phase insulin secretion by 118 and 103%, respectively (P < 0.05).
… two highest dose levels vs. placebo by 114 and 94%, respectively (P < 0.05).
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
First-phase insulin secretion1.25 mg/day liraglutide vs placebo
118
First-phase insulin secretion1.9 mg/day liraglutide vs placebo
103
Arginine-stimulated insulin secretion1.25 mg/day liraglutide vs placebo
114
Arginine-stimulated insulin secretion1.9 mg/day liraglutide vs placebo
94
GLP-1 receptor agonistsGlycemic control
1 / 4